4-(5,7-DIOXO-5H-PYRROLO[3,4-B]PYRAZIN-6(7H)-YL)BENZOIC ACID


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	XDAJHYFGFMWBOF-UHFFFAOYSA-N
Smiles	OC(=O)c1ccc(cc1)N2C(=O)c3nccnc3C2=O
InChI	InChI=1S/C13H7N3O4/c17-11-9-10(15-6-5-14-9)12(18)16(11)8-3-1-7(2-4-8)13(19)20/h1-6H,(H,19,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H7N3O4
Molecular Weight	269.21
AlogP	0.62
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	100.46
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Antibacterial activity against Pseudomonas aeruginosa assessed as growth inhibition after 24 hr by two-fold serial dilution method	Pseudomonas aeruginosa	100.0 ug.mL-1
Antibacterial activity against Escherichia coli assessed as growth inhibition after 24 hr by two-fold serial dilution method	Escherichia coli	4.39	Antibacterial activity against Escherichia coli assessed as growth inhibition after 24 hr by two-fold serial dilution method	Escherichia coli	10.9 ug.mL-1
Antibacterial activity against Bacillus subtilis assessed as growth inhibition after 24 hr by two fold serial dilution method	Bacillus subtilis	8.0 ug.mL-1
Antibacterial activity against Staphylococcus aureus assessed as growth inhibition after 24 hr by two fold serial dilution method	Staphylococcus aureus	4.5	Antibacterial activity against Staphylococcus aureus assessed as growth inhibition after 24 hr by two fold serial dilution method	Staphylococcus aureus	8.5 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2377777
PubChem	4583704

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).